Inhibiting human integrin (alpha-4) (beta-7)

A compound of Formula (I):

• wherein
• Ra, Rb, and Re are independently selected from the group consisting of H, Me, halide, CF3, C(H)F2, C(F)H2, and —(C1-C5)alkylene-N—(Rx)(Ry);
• provided that at least one of Ra, Rb, and Rc is —(C1-C5)alkylene-N—(Rx)(Ry);
• Rx and Ry are independently selected from the group consisting of H and substituted or unsubstituted (C1-C6)-alkyl;
• or Rx and Ry taken together with the N to which they are attached form a 4-6 membered ring;
• R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or t-butyl;
• R2 is
• R3a and R3b are independently selected from the group consisting of H, (C1-C5)-alkyl, (C3-C6)-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, —OH, —CN, halide, CF3, C(H)F2, C(F)H2, —(C1-C4)-alkoxy, —OCF3, and substituted or unsubstituted (C1-C4)-alkylene-(C1-C4)-alkoxy;
• provided that R3a and R3b are not both H;
• R3c, and R3d are H;
• R4 is H;
• R5a, and R5e are independently methyl;
• R5b, and R5c are independently selected from the group consisting of H, CN, halide, CF3, C(H)F2, C(F)H2, substituted or unsubstituted (C1-C5)-alkyl, substituted or unsubstituted (C3-C6)-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C1-C4)-alkoxy;
• R5d is H;
• and
• wherein the compound of Formula (I) is selected from the group consisting of:
• a. (S)-3-(4,5-difluoro-2′,6′-dimethyl-[1,1′-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid;
• b. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2′,6′-dimethyl-5-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)propanoic acid;
• c. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3′,4-difluoro-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)propanoic acid;
• d. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3′-methoxy-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)propanoic acid;
• e. (S)-3-(4,4′-difluoro-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid;
• f. (S)-3-(5-chloro-4-fluoro-2′,6′-dimethyl-[1,1′-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid;
• g. (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2′,4′,5,6′-tetramethyl-[1,1′-biphenyl]-3-yl)propanoic acid;
• h. (S)-3-(4,4′-difluoro-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)-3-((S)-2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid;
• i. (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)propanoic acid;
• j. (S)-3-(4-fluoro-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid;
• and
• k. (S)-3-(4-fluoro-2′,5,6′-trimethyl-[1,1′-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid;
• or a pharmaceutically acceptable salt thereof.